Navigation Links
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Date:3/20/2008

- First New Agent for CLL Patients Approved by the FDA since 2001 -

FRAZER, Pa., March 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. The American Cancer Society estimates that more than 15,000 new cases of this rare disease will be diagnosed in the United States this year. The TREANDA application as a CLL treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon anticipates that TREANDA will be available to physicians and patients as a CLL treatment in the United States in April 2008.

To view the Multimedia News Release, go to:

http://www.prnewswire.com/mnr/treanda/32349/.

"TREANDA is an important new treatment for patients with chronic lymphocytic leukemia, and this first-cycle approval by FDA represents a significant milestone in the growth of our oncology business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "With a strong pipeline of near- and longer-term opportunities, Cephalon Oncology is poised to deliver therapies that target both hematologic cancers and solid tumors for patients in need of new options."

Dr. Bruce Cheson, Clinical Professor of Hematology/Oncology, Georgetown University School of Medicine, Washington D.C., stated, "Patients with chronic lymphocytic leukemia can often live normal lives for many years because of treatments that control the disease over the long-term. TREANDA is an effective new option that offers a delay in disease progression, an important goal for patients with chronic lymphocytic leukemia."

In a randomized, international, m
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
2. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
3. Cephalon General Counsel John E. Osborn to Resign Position
4. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
5. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
6. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
8. Cephalon Submits Supplemental New Drug Application for FENTORA
9. Cephalon Announces Strong Third Quarter Financial Results
10. Cephalon Quarterly Conference Call Invitation
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) ... of Appeals for the D.C. Circuit challenging the FAA’s Interpretation ... Federal Register on June 25, 2014. , The AMA ... text and intent of the FAA Modernization and Reform Act ... on any new rules or regulations regarding model aircraft that ...
(Date:8/22/2014)... direct observations of how facets form and develop ... sophisticated and effective nanocrystal design and reveal that ... growth breaks down at the nanoscale. , Researchers ... Berkeley National Laboratory (Berkeley Lab) used highly sophisticated ... camera to capture the physical mechanisms that ...
(Date:8/22/2014)... 2014 Research and Markets has ... Gel Permeation Chromatography (GPC) Industry Report 2014" report ... China Gel Permeation Chromatography (GPC) Industry Report is a ... the global gel permeation chromatography industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The ... model organisms can be accelerated by exome sequencing. ... manufacturing technologies, the custom SeqCap EZ Developer system ... , Mr. Watson will additionally present how he ... commercially available human and mouse exome kits. With ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... Cedara Software said it has acquired through ... medical software company in Paris. Cedara is he Toronto-based ... information technology company headquartered in Milwaukee. , ,It will ... managment, which has been installed in 25 French facilities. ...
... revenues for the quarter ended December 31 were up 18 ... quarter, compared to $1.6 million a year ago. , ,A ... this year and projected cashflow break-even sometime in the next ... net loss was $1.6 million for the quarter, compared to ...
... Fifty-two University of Wisconsin undergrads are going to ... Thursday and Friday for creative inventions that could turn ... for Creativity and Tong Prototype Prize reward students for ... At this year's Innovation Days, undergrads will show off ...
Cached Biology Technology:
(Date:8/21/2014)... international standards process, will be available soon and will ... published in the OnlineFirst version of Nutrition in ... of the American Society for Parenteral and Enteral Nutrition ... of misconnection that can be harmful and even fatal ... join medical devices, components, and accessories to deliver fluids ...
(Date:8/21/2014)... have developed a novel and versatile modeling strategy to ... new materials as well as for studying polyelectrolytes, including ... to model much larger and more complex polyelectrolyte systems, ... Li, lead author of a paper on the work ... Materials Science and Engineering. "This is a big step ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2
... High-intensity focused ultrasound emitted in short pulses is ... to cancerous cells without destroying healthy tissue, according ... the journal Radiology. , High-intensity focused ultrasound (HIFU) ... destroy tumors through long and continuous exposures that ...
... grow these cells are costly and don't produce cells ... embryonic stem cells, said Shang-Tian Yang, a professor of ... Federal rules forbid the federal funding of research on ... the National Institutes of Health's Human Embryonic Stem Cell ...
... of the NIH public access policy announced earlier this ... , BioMed Central welcomes the announcement of the ... The NIH calls on all of its grantees to deposit ... of Medicine's PubMed Central and make them freely available within ...
Cached Biology News:Pulsating ultrasound enhances gene therapy for tumors 2Researchers devise way to mass-produce embryonic stem cells 2Researchers devise way to mass-produce embryonic stem cells 3BioMed Central welcomes the new National Institutes of Health public access policy 2
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Component in MasterPure™ Purification Kits...
Chlamydia pneumoniae (TWAR)...
Biology Products: